Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

Pfizer's going to rocket?I didn't take a look at Pfizer for quite a while, but just recently going through the list of my favourite stocks I noticed it from the first glance. Something is going to happen... This declining volume, overlapping of price and a bit of a volume spike on 11th August, all seems to be in line. The 3rd wave formed in December 2021 and we had a correction for almost a year, now it's time to move on. Fly PFE fly! Invalidation point is 46.28, with min target of 61-65. Good luck trader!
NYSE:PFELong
by rO_Oute
4
Pfeizer peaked, now losing momentum. PFEGoals 0.56, 0.49. Invalidation at 0.89. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:PFEShort
by Rykin_Capital
PFE: Triangle break!Pfizer Short Term - We look to Sell at 50.48 (stop at 52.47) Our outlook is bearish. Broken out of the triangle formation to the downside. This is negative for sentiment and the downtrend has potential to return. Further downside is expected although we prefer to sell into rallies close to the 51.00 level. Our profit targets will be 45.49 and 42.00 Resistance: 50.00 / 54.00 / 62.00 Support: 45.00 / 40.00 / 34.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:PFEShort
by VantageMarkets
Pfizer | Fundamental Analysis | Must ReadSo far this year has not been kind to stock markets. And while many drug makers have avoided a selloff, Pfizer is not one of them. The pharmaceutical giant has performed more or less on par with the broader market to date. Fortunately, Pfizer's latest quarterly report showed some very encouraging signs. However, there are also reasons to be concerned about the future of this medical company. Let's look at one earnings-related reason why Pfizer might be a buy and one reason why it might not be. Pfizer has made a fortune over the past couple of years through its work on coronaviruses. The company continues to benefit greatly from these efforts. In Q2, the company's revenues rose 53% year over year to $27.7 billion. According to company executives, Pfizer recorded the largest quarterly sales in its history during the period, and that was primarily due to its COVID-19 product line. Sales of the coronavirus vaccine totaled $8.8 billion, up 20% from last year. Sales of the coronavirus drug Paxlovid were $8.1 billion (no year-over-year comparison here, since the drug received approval in December). These two drugs alone accounted for more than half of Pfizer's total revenue. While Pfizer's line of drugs against coronaviruses is currently unparalleled, the rest of the company's portfolio is not as impressive. The non-coronavirus drug maker's revenues grew a paltry 1% year-over-year in Q2. Pfizer's line of drugs faces a number of challenges, including adverse events related to its immunologic drug Xeljanz. Xeljanz belongs to a class of drugs known as JAK inhibitors. Last year, Pfizer published data from a post-marketing study that showed Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a drug category that includes AbbVie's Humira. The results of this study, combined with a regulatory decision to add a warning about these risks to the label of Xeljanz (and other JAK inhibitors), are holding back sales of the drug. In Q2, sales of Xeljanz declined 24% year over year to $430 million. Revenues for the immunosuppressant Enbrel also fell 10% year over year to $257 million, probably because of tougher competition, which also affected its sales in Q1. Pfizer has some good non-coronavirus numbers, including its drug Eliquis. In Q2, sales of that anticoagulant rose 23% year over year to $1.7 billion. But overall, the company has barely been able to increase sales outside of its line of coronavirus drugs. This could be a problem if sales of COVID-19 products fall sharply after this year. In my opinion, the market is still underestimating Pfizer. First, the company will continue to make profits from Paclovid and Comirnati. COVID-19 will not (unfortunately) suddenly disappear out of thin air after this year. Even if the demand for drugs to prevent or treat the disease declines, Paxlovid and Komirnati can continue to make significant contributions to Pfizer's top-line revenue for a long time to come. Second, while the rest of the drug line is unimpressive, pharmaceutical companies sometimes face this problem because of growing competition, patent breaks, or other factors. But drug makers generally don't have the advantage of growing sales at the rate that Pfizer does when they face such obstacles. What matters is whether the company in question can meet these challenges. Having a solid portfolio and plenty of money to devote to research and development helps - and Pfizer has both. Thanks to the company's success in the coronavirus market, its cash balance has skyrocketed. Pfizer has been active in acquisitions and plans to continue on that path. This should help bolster its already solid line of drugs, which has more than 90 clinical trials. Pfizer expects up to 15 new approvals over the next 18 months. Some of the current programs could go wrong. But the company has all the tools it needs to launch several new potential blockbuster drugs in the next five years. That's why investors should siphon off the company's stock before it rises in price.
NYSE:PFELong
by FOREXN1
10
Symmetrical Triangle/Rising Wedge.Earnings 7-28 BMO Neutral pattern until a trendline is broken. Targets over the triangle are bullish targets if triangle breaks to the upside. Targets below the structure are bearish targets if this breaks to the downside. Price has broken bottom trendline of the triangle and recovered using a prior gap as support. Doji candle on Friday/indecision. Short percent is 1.23% approximate and ratio is 2.9. Earnings can make going long or short tricky so I will wait and see what happens. Longer term I feel this is a short due to the rising wedge. You may see this chart differently than I do. No recommendation. There is an old bearish rising wedge ( LOOK LEFT) in this chart just below $40. This pattern has not been validated. This pattern is not valid until the bottom trendline is broken. If history repeats itself, this rising wedge will eventually be broken.
NYSE:PFEShort
by lauralea
1
$PFE is finding support at its 50 day line. Can it move higher?Notes: * Strong up trend on all time frames * Great earnings track record * Building a base for the past ~7months * Consolidating around its 50 day line with decreasing volume on the daily, weekly and monthly time frames * This indicates that the buyers and sellers are agreeing on this price range * Currently bouncing off of its 50 day line with higher than average volume Technicals: Sector: Healthcare - Drug Manufacturers - General Relative Strength vs. Sector: 1.22 Relative Strength vs. SP500: 1.11 U/D Ratio: 1.65 Base Depth: 33.25% Distance from breakout buy point: -14.42% Volume 7.08% above its 15 day avg. Trade Idea: * This is offering a low risk entry * You can enter now as the price is just bouncing off of its 50 day line with higher than average volume * If you're looking for a better entry you can look for one around the 50.67 area as that should serve as support * This stock usually has local tops when the price closes around 14.24% above its 50 EMA * Consider selling into strength if the price closes 14.04% to 14.44% (or higher) above its 50 EMA * The last closing price is 0.98% away from its 50 EMA
NYSE:PFELong
by HaseebKhan_90
Here's an easy support & resistance strategyAccumulate in the lower part of the lines. You can use this to accumulate a dividend stock of an extremely fundamentally sound company. We can do this for a certain time after we notice a channel pattern form. I am not a financial advisor and this is not financial advice. This is for paper trading or simulated trading practices only. Trading is risky and you should consult with a financial advisor before taking on any risk. Any risk taken is your own doing and I will not be liable for your actions.
NYSE:PFELong
by WatsonsView
Pfizer: Playing the range againPfizer Short Term We look to Sell at 54.06 (stop at 56.08) Bespoke resistance is located at 54.50. A move higher faces tough resistance and we remain cautious on upside potential. Selling spikes offers good risk/reward. Further downside is expected although we prefer to sell into rallies close to the 54.60 level. We are trading at overbought extremes. Our profit targets will be 46.80 and 44.60 Resistance: 54.50 / 56.32 / 61.71 Support: 50.00 / 46.50 / 40.94 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo